布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的疗效

Efficacy of budesonide formoterol combined with tiotropium bromide in the treatment of stable chronic obstructive pulmonary disease

目的研究慢性阻塞性肺疾病(慢阻肺)稳定期患者应用布地奈德福莫特罗联合噻托溴铵治疗的效果。方法68例慢阻肺稳定期患者,随机分为研究组及对照组,每组34例。两组患者均予以常规治疗措施,在此基础上,对照组患者使用布地奈德福莫特罗治疗,研究组患者使用布地奈德福莫特罗联合噻托溴铵治疗。对比两组患者的临床疗效、生活质量评分、肺功能指标[第1秒用力呼气容积(FEV1)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)、第1秒用力呼气容积占预计值的百分比(FEV1%)]。结果研究组患者的总有效率94.1%高于对照组的73.5%,差异具有统计学意义(P<0.05)。研究组患者的社会功能、情绪功能、认知功能、角色功能、躯体功能评分分别为(17.59±1.69)、(17.59±2.10)、(17.19±2.22)、(17.97±1.86)、(18.57±2.13)分,均高于对照组的(14.90±1.83)、(15.03±1.77)、(14.67±1.58)、(14.79±1.63)、(15.29±1.59)分,差异具有统计学意义(P<0.05)。治疗前,两组患者的FEV1、FEV1/FVC、FEV1%比较,差异无统计学意义(P>0.05);治疗后,研究组患者的FEV1(2.92±0.17)L、FEV1/FVC(78.47±6.70)%、FEV1%(74.68±5.79)%均高于对照组的(2.16±0.19)L、(69.21±6.88)%、(65.41±5.27)%,差异具有统计学意义(P<0.05)。结论慢阻肺稳定期患者使用布地奈德福莫特罗联合噻托溴铵治疗,能够促进患者肺功能改善,提高其生活质量,促进症状缓解,临床治疗效果好,具有重要的应用价值。

Objective To study the effect of budesonide formoterol combined with tiotropium bromide in the treatment of stable chronic obstructive pulmonary disease.Methods A total of 68 patients with stable chronic obstructive pulmonary disease were randomly divided into research group and control group,with 34 cases in each group.Both groups received conventional therapy.On this basis,the control group was treated with budesonide formoterol,and the research group was treated with budesonide formoterol and tiotropium bromide.The clinical efficacy,quality of life score,pulmonary function indicators[forced expiratory volume in the first second(FEV1),FEV1/forced vital capacity(FEV1/FVC),and forced expiratory volume in the first second as a percentage of the predicted value(FEV1%)]were compared between the two groups.Results The total effective rate 94.1%of the research group was higher than 73.5%of the control group,and the difference was statistically significant(P<0.05).The social function,emotional function,cognitive function,role function,physical function score of the research group were(17.59±1.69),(17.59±2.10),(17.19±2.22),(17.97±1.86)and(18.57±2.13)points,which were higher than(14.90±1.83),(15.03±1.77),(14.67±1.58),(14.79±1.63)and(15.29±1.59)points of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in FEV1,FEV1/FVC and FEV1%between the two groups(P>0.05).After treatment,the FEV1(2.92±0.17)L,FEV1/FVC(78.47±6.70)%and FEV1%(74.68±5.79)%of the research group were higher than(2.16±0.19)L,(69.21±6.88)%and(65.41±5.27)%of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of budesonide formoterol and tiotropium bromide has good clinical effect on patients with stable chronic obstructive pulmonary disease,and it can improve the quality of life and promote the symptom remission.It contains great practical value.